Form 4: Chimerix Inc. Executive David Jakeman Reports Stock and Option Awards

David Jakeman, VP of Finance and Accounting at Chimerix Inc., reported the acquisition of 10,855 shares of common stock and 65,000 stock options.

Summary

• David Jakeman, VP of Finance and Accounting at Chimerix Inc., has reported a transaction involving the acquisition of company stock and stock options.
• On January 7, 2025, Jakeman acquired 10,855 shares of common stock through restricted stock units (RSUs).
• These RSUs will vest over four years, with 2,713 shares vesting on the first anniversary, and 2,714 shares vesting on each of the subsequent three anniversaries.
• Additionally, Jakeman acquired 65,000 stock options with an exercise price of $3.66.
• These options vest over four years, with one-fourth vesting on the first anniversary and the remainder vesting monthly over the following three years.
• Following these transactions, Jakeman now beneficially owns 152,087 shares of common stock and 65,000 stock options.

Sentiment

Score: 7

Explanation: The document reflects standard executive compensation practices, which is generally viewed positively as it aligns management with shareholder interests. There are no negative implications.

Positives

• The granting of stock options and restricted stock units to a key executive like the VP of Finance and Accounting can be seen as a positive incentive for performance and alignment with shareholder interests.
• The vesting schedule of the RSUs and stock options encourages long-term commitment from the executive.

Risks

• The vesting of the RSUs and stock options could potentially dilute existing shareholders if the options are exercised and the shares are issued.
• The value of the stock options is dependent on the future performance of the company's stock price.

Future Outlook

The vesting of the RSUs and stock options will occur over the next four years, contingent on the executive's continued employment.

Industry Context

This type of equity compensation is common practice in the biotechnology industry to attract and retain key talent. It aligns executive interests with those of shareholders by incentivizing long-term value creation.

Comparison to Industry Standards

• Equity grants, including stock options and restricted stock units, are a standard component of compensation packages for executives in the biotechnology sector.
• Companies like Gilead Sciences, Amgen, and Biogen also use similar equity-based compensation to incentivize their executives.
• The vesting schedules of these grants are also typical, with vesting periods ranging from three to five years, often with a cliff vesting period followed by monthly or quarterly vesting.

Stakeholder Impact

• Shareholders may view the equity grants positively as they align executive interests with long-term company performance.
• Employees may see this as a positive sign of the company's commitment to its leadership team.

Key Dates

Keywords

Chimerix, stock options, restricted stock units, insider trading, executive compensation, equity awards, Form 4, David Jakeman